VIVEX Biologics, Inc. announces Lisa Colleran as the new CEO of the company
Atlanta, Ga., Miami, FL., October 16, 2018 — VIVEX Biologics, Inc., a leading Regenerative Medicine company, announced today that Lisa Colleran has been appointed the new CEO. Ms. Colleran is an experienced leader in the field of Regenerative Medicine and known in the industry for delivering strong business results and successfully creating shareholder value.
Former President, CEO and founder of VIVEX, Tracy Anderson will transition from the company’s CEO to take on the role of Vice Chairman. Anderson will remain on the VIVEX Board of Directors. “Tracy has done an incredible job as the founder and CEO of VIVEX, creating a leading tissue and cell therapy company with scientifically-based technologies, an unsurpassed patent portfolio and significant revenue in the spine and orthopaedic space.” says Bert Ellis, Chairman of the Board. “His leadership and innovative approach sets the company up for incredible success as we move into the next phase of growth.”
Ms. Colleran was the former CEO of LifeCell Corporation. During her 11-year tenure, LifeCell became one of the most successful medical device companies in plastic and general surgery. In the first 6 years of her tenure, LifeCell’s annual revenues grew from $25 million to approximately $200 million and its market valuation increased from $100 million to $1.7 billion, when LifeCell was sold in 2008 to a large medical device company. After the sale of the company, Lisa stayed on and lead the company through a second ownership transition, doubling the revenue to almost $400 million and creating significant shareholder value. Prior to joining LifeCell, Lisa spent 20 years at Baxter Healthcare in various commercial and general management roles.
“We are very excited about Lisa Colleran joining the VIVEX family as the company transitions to the next phase. She brings a wealth of experience that we believe will vault VIVEX to new levels of excellence. Although it has been my greatest honor running VIVEX since its inception, this change in leadership is a natural progression that will benefit all of our stakeholders,” said Tracy Anderson.
“I couldn’t be more thrilled to join VIVEX at this very exciting juncture in the company’s evolution. The team at VIVEX has built something unique, and I am honored to be a part of it. The current products have been proven to add clinical value to a wide variety of surgical procedures and the future products have the potential to completely change treatment paradigms, improving clinical outcomes for patients around the world”, stated Ms. Colleran.
About VIVEX Biologics, Inc.:
VIVEX is a regenerative biomedical company dedicated to creating new standards in patient care. VIVEX strives to create treatment options and solutions that will improve clinical, surgical, and therapeutic patient care through innovation. Under the guidance of experienced and successful business professionals, VIVEX engages the brightest minds from the medical and material science industries to explore new and different ways to help others. VIVEX works with services that are committed to providing care and compassion to donor families while inspiring communities to share life through their donations. Partnering with families in the prospect of regenerative options, VIVEX assures appropriate options are available to support regeneration and translation of their gifts.
Safe Harbor Statements: This press release contains forward-looking statements. These forward-looking statements are based on our current assumptions, expectations, and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties, and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, without limitation, factors affecting our financial results, demand for our products, our ability to obtain regulatory clearance or approval, where necessary, from the U.S. Food and Drug Administration, our ability to compete successfully, our ability to safeguard our intellectual property, and our ability to comply with laws and regulations that are or may become applicable to our businesses. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements.